The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
Open accessAbstract
BACKGROUND: Effective ways to prevent arthropathy in severe hemophilia are unknown. METHODS: We randomly assigned young boys with severe hemophilia A to regular infusions of recombinant factor VIII (prophylaxis) or to an enhanced episodic infusion schedule of at least three doses totaling a minimum of 80 IU of factor VIII per kilogram of body weight at the time of a joint hemorrhage. The primary outcome was the incidence of bone or cartilage damage as detected in index joints (ankles, knees, and elbows) by radiography or magnetic resonance imaging (MRI). RESULTS: Sixty-five boys younger than 30 months of age were randomly assigned to prophylaxis (32 boys) or enhanced episodic therapy (33 boys). When the boys reached 6 years of age, 93% of those in the prophylaxis group and 55% of those in the episodic-therapy group were considered to have normal index-joint structure on MRI (P=0.006). The relative risk of MRI-detected joint damage with episodic therapy as compared with prophylaxis was 6.1 (95% confidence interval, 1.5 to 24.4). The mean annual numbers of joint and total hemorrhages were higher at study exit in the episodic-therapy group than in the prophylaxis group (P<0.001 for both comparisons). High titers of inhibitors of factor VIII developed in two boys who received prophylaxis; three boys in the episodic-therapy group had a life-threatening hemorrhage. Hospitalizations and infections associated with central-catheter placement did not differ significantly between the two groups. CONCLUSIONS: Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. (ClinicalTrials.gov number, NCT00207597 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although effective, ERT is limited by an approximately 40% noncompliance rate, costs ≥$200,000 annually, and advances arthropathy.172, 173, 174, 175”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [172]
Citations
Cites
Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B
NILSSON, I. M., BERNTORP, E., LÖFQVIST, T., & PETTERSSON, H. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00546.x · Cited by 961
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
ALEDORT, L. M., HASCHMEYER, R. H., PETTERSSON, H., & THE ORTHOPAEDIC OUTCOME STUDY GROUP (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb00815.x · Cited by 611
A Radiologic Classification of Hemophilic Arthropathy
PETTERSSON, H., AHLBERG, Å., & NILSSON, I. M. (1980) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198006000-00018 · Cited by 549
Proceedings: A more uniform measurement of factor VIII inhibitors.
Ck, K., Aledort, L. M., Aronson, D. D., Counts, R., Edson, van Eys, J., Fratantoni, J. C., Green, D., Hampton, J., Hilgartner, M. W., et al. (1975) · PubMed · Cited by 346
Barriers to compliance with prophylaxis therapy in haemophilia
Hacker, M. R., Geraghty, S., & Manco-Johnson, M. (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00534.x · Cited by 261
Self-citationAhlberg, Å. (1965) · Acta Orthopaedica Scandinavica · doi:10.3109/ort.1965.36.suppl-77.01 · Cited by 252
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors
Soucie, J. M. (2004) · Blood · doi:10.1182/blood-2003-05-1457 · Cited by 244
Self-citationIorio, A., Marchesini, E., Marcucci, M., Stobart, K., & Chan, A. K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003429.pub4 · Cited by 192
Nuss, R., Kilcoyne, R. F., Geraghty, S., Shroyer, A. L. W., Rosky, J. W., Mawhinney, S., Wiedel, J., & Manco‐Johnson, M. (2000) · Haemophilia · doi:10.1046/j.1365-2516.2000.00383.x · Cited by 159
Self-citationLee, C. A., Kessler, C. M., Varon, D., Martinowitz, U. P., Heim, M., Kreuz, W., Escuriola‐Ettingshausen, C., Funk, M. J., SCHMIDT, H., & Kornhuber, B. (1998) · Haemophilia · doi:10.1046/j.1365-2516.1998.440413.x · Cited by 154
Research works printed but not linked: 5
- Robinson PM, 1967, Can Med Assoc J, 97, 559
- Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis. Medical bulletin #193. New York: National Hemophilia Foundation, March 11, 1994.
- Stobart K, 2006, Cochrane Database Syst Rev, 2, CD003429
- Kasper CK, 1975, Thromb Diath Haemorr, 34, 612
- Report on the Universal Data Collection Program. Atlanta: Centers for Disease Control and Prevention, 2005;7(1):28. (Accessed July 18, 2007, athttp://www.cdc.gov/ncbddd/hbd/documents/UDC7%281%29.pdf.)
Cited by
Guidelines for the management of hemophilia
Srivastava, A., Brewer, A. K., Mauser‐Bunschoten, E. P., Key, N. S., Kitchen, S., Llinas, A., Ludlam, C. A., Mahlangu, J. N., Mulder, K., Poon, M. C., et al. (2013) · Haemophilia · doi:10.1111/j.1365-2516.2012.02909.x · Cited by 1,927
“A dental evaluation is advisable before initiating long-term bisphosphonate therapy [28,29].”
BackgroundTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
“The disease is currently treated by intravenous infusion of clotting factor concentrate”
BackgroundDefinitions in hemophilia: communication from the SSC of the ISTH
Blanchette, V. S., Key, N. S., Ljung, L. R., Manco‐Johnson, M. J., van den Berg, H. M., & Srivastava, A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12672 · Cited by 761
Self-citationCurrent clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“replacement therapy (ERT) delivered prophylactically to prevent or on demand for bleeding.(172,173) Although effective, ERT is limited by an approximately 40% noncompliance rate, costs R$200,000 annually, and advances arthropathy.”
MethodAAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
Kitazawa, T., Igawa, T., Sampei, Z., Muto, A., Kojima, T., Soeda, T., Yoshihashi, K., Okuyama-Nishida, Y., Saito, H., Tsunoda, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2942 · Cited by 507
The past and future of haemophilia: diagnosis, treatments, and its complications
Peyvandi, F., Garagiola, I., & Young, G. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01123-x · Cited by 505
Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Shima, M., Hanabusa, H., Taki, M., Matsushita, T., Sato, T., Fukutake, K., Fukazawa, N., Yoneyama, K., Yoshida, H., & Nogami, K. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1511769 · Cited by 478
“Upper respiratory tract infection 0 1 0 1 (6)”
BackgroundInfluentialA randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)
GRINGERI, A., LUNDIN, B., VON MACKENSEN, S., MANTOVANI, L., & MANNUCCI, P. M. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04214.x · Cited by 454
Young, G., Liesner, R., Chang, T., Sidonio, R., Oldenburg, J., Jiménez-Yuste, V., Mahlangu, J., Kruse-Jarres, R., Wang, M., Uguen, M., et al. (2019) · Blood · doi:10.1182/blood.2019001869 · Cited by 402
Oldenburg, J. (2015) · Blood · doi:10.1182/blood-2015-01-528414 · Cited by 376
“5.(5,20,41-43) Given the long-termdimensionofdeveloping joint arthropathyand the limitations of diagnosing early joint damage the ABR serves as an important clinical parameter to adjust treatment regimens.”
BackgroundResultInfluentialTargeting of Antithrombin in Hemophilia A or B with RNAi Therapy
Pasi, K. J., Rangarajan, S., Georgiev, P., Mant, T., Creagh, M. D., Lissitchkov, T., Bevan, D., Austin, S., Hay, C. R., Hegemann, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616569 · Cited by 367
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
Powell, J. S., Pasi, K. J., Ragni, M. V., Ozelo, M. C., Valentino, L. A., Mahlangu, J. N., Josephson, N. C., Perry, D., Manco-Johnson, M. J., Apte, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305074 · Cited by 365
Self-citationSampei, Z., Igawa, T., Soeda, T., Okuyama-Nishida, Y., Moriyama, C., Wakabayashi, T., Tanaka, E., Muto, A., Kojima, T., Kitazawa, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057479 · Cited by 336
“quality of life in hemophilia A patients [2].”
BackgroundBerntorp, E., & Shapiro, A. D. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61139-2 · Cited by 335
Self-citationGouw, S. C., van den Berg, H. M., Fischer, K., Auerswald, G., Carcao, M., Chalmers, E., Chambost, H., Kurnik, K., Liesner, R., Petrini, P., et al. (2013) · Blood · doi:10.1182/blood-2012-09-457036 · Cited by 332
“exposure days at intention to start prophylaxis 5 (2-12) 0-74”
BackgroundBerntorp, E., Fischer, K., Hart, D. P., Mancuso, M. E., Stephensen, D., Shapiro, A. D., & Blanchette, V. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00278-x · Cited by 328
Self-citationCollins, P. W., Blanchette, V. S., Fischer, K., Björkman, S., Oh, M., Fritsch, S., Schroth, P., Spotts, G., Astermark, J., & Ewenstein, B. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03270.x · Cited by 323
Hemophilic arthropathy: Current knowledge and future perspectives
Gualtierotti, R., Solimeno, L. P., & Peyvandi, F. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15444 · Cited by 307
Gene Therapy With Adeno-Associated Virus Vector 5-Human Factor IX in Adults With Hemophilia B
Miesbach, W., Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R., Tangelder, M., Castaman, G., Schwäble, J., Bonig, H., et al. (2018) · Blood · doi:10.1182/blood-2017-09-804419 · Cited by 301
“Hemophilia Joint Health Scores‡ 27 (2-49) 6 (0-17)”
Blood‐induced joint disease: the pathophysiology of hemophilic arthropathy
VALENTINO, L. A. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03962.x · Cited by 294
Self-citationFeldman, B. M., Funk, S. M., Bergstrom, B., Zourikian, N., Hilliard, P., van der Net, J., Engelbert, R., Petrini, P., van den Berg, H. M., Manco‐Johnson, M. J., et al. (2011) · Arthritis Care & Research · doi:10.1002/acr.20353 · Cited by 289
Self-citationPast, present and future of hemophilia: a narrative review
Franchini, M., & Mannucci, P. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-24 · Cited by 281
“While primary prophylaxis remains the gold standard for preserving joint function in babies with severe hemophilia [48], there is actually a debate regarding the effects on joint status of secondary prophylaxis compared with on demand therapy in older children, adolescents and adults [49].”
BackgroundLenting, P. J., Denis, C. V., & Christophe, O. D. (2017) · Blood · doi:10.1182/blood-2017-08-801662 · Cited by 269
Konkle, B. A., Stasyshyn, O., Chowdary, P., Bevan, D. H., Mant, T., Shima, M., Engl, W., Dyck-Jones, J., Fuerlinger, M., Patrone, L., et al. (2015) · Blood · doi:10.1182/blood-2015-03-630897 · Cited by 262
Uchida, N., Sambe, T., Yoneyama, K., Fukazawa, N., Kawanishi, T., Kobayashi, S., & Shima, M. (2016) · Blood · doi:10.1182/blood-2015-06-650226 · Cited by 260
“However, this current standard treatment of hemophilia A(4) incurs a considerable physical and mental burden on patients and their families.(3,5) The use of FVIII agents is complicated by interindividual variability in FVIII pharmacokinetics (PK)(1,6) and requires dose or dosing frequency adjustment to maintain FVIII:…”
Alberighi, O. D., Di Minno, G., Graziano, E., Molinari, A. C., Pasta, G., Russo, G., Santagostino, E., Tagliaferri, A., Tagliafico, A., Morfini, M., et al. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-11-0874 · Cited by 257
“A) Anterior mid-sagittal US image demonstrates the patella (1) and the distal femur (2).”
BackgroundInfluentialVALENTINO, L. A., MAMONOV, V., HELLMANN, A., QUON, D. V., CHYBICKA, A., SCHROTH, P., PATRONE, L., & WONG, W. ‐. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04611.x · Cited by 253
Self-citationMultiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A
George, L. A., Monahan, P. E., Eyster, M. E., Sullivan, S. K., Ragni, M. V., Croteau, S. E., Rasko, J. E. J., Recht, M., Samelson-Jones, B. J., MacDougall, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104205 · Cited by 243
Self-citationSafety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
Powell, J. S., Josephson, N. C., Quon, D., Ragni, M. V., Cheng, G., Li, E., Jiang, H., Li, L., Dumont, J. A., Goyal, J., et al. (2012) · Blood · doi:10.1182/blood-2011-09-382846 · Cited by 240
“on primary prophylaxis after their first joint bleed had significantly fewer bleeds and less joint damage than children treated on-demand.(3) Compared to on-demand treatment, prophylactic therapy also decreases disability, hospitalization rate, and time lost from school or work;(6,17) and improves quality of life for…”
BackgroundFactor VIII inhibitors in hemophilia A: rationale and latest evidence
Witmer, C., & Young, G. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620712464509 · Cited by 231
Li, C., Narkbunnam, N., Samulski, R. J., Asokan, A., Hu, G., Jacobson, L. J., Manco-Johnson, M. J., Monahan, P. E., & The Joint Outcome Study Investigators (2012) · Gene Therapy · doi:10.1038/gt.2011.90 · Cited by 225
Self-citationHemophilia therapy: the future has begun
Mannucci, P. M. (2020) · Haematologica · doi:10.3324/haematol.2019.232132 · Cited by 223
Fischer, K., Steen Carlsson, K., Petrini, P., Holmström, M., Ljung, R., van den Berg, H. M., & Berntorp, E. (2013) · Blood · doi:10.1182/blood-2012-12-470898 · Cited by 220
“At this time, prophylactic dosing is mostly based on the Swedish regimen of 25 to 40 IU/kg per infusion, and dosages used in pediatric trials have been consistently high, at 25 IU/kg thrice weekly or every other day (ie, 3900 and 4550 IU/kg per year, respectively).(6,7) For older patients, guidelines on dosing are una…”
BackgroundAnti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors
Leissinger, C., Gringeri, A., Antmen, B., Berntorp, E., Biasoli, C., Carpenter, S., Cortesi, P., Jo, H., Kavakli, K., Lassila, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104435 · Cited by 221
Self-citationSANTAGOSTINO, E., MANCUSO, M. E., TRIPODI, A., CHANTARANGKUL, V., CLERICI, M., GARAGIOLA, I., & MANNUCCI, P. M. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03767.x · Cited by 217
DEN UIJL, I. E. M., FISCHER, K., VAN DER BOM, J. G., GROBBEE, D. E., ROSENDAAL, F. R., & PLUG, I. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2010.02383.x · Cited by 214
European principles of haemophilia care
COLVIN, B. T., ASTERMARK, J., FISCHER, K., GRINGERI, A., LASSILA, R., SCHRAMM, W., THOMAS, A., INGERSLEV, J., & FOR THE INTER DISCIPLINARY WORKING GROUP (2008) · Haemophilia · doi:10.1111/j.1365-2516.2007.01625.x · Cited by 210
COLLINS, P. W., FISCHER, K., MORFINI, M., BLANCHETTE, V. S., BJÖRKMAN, S., & ON BEHALF OF INTERNATIONAL PROPHYLAXIS STUDY GROUP (IPSG) PHARMACOKINETICS EXPERT WORKING GROUP (2011) · Haemophilia · doi:10.1111/j.1365-2516.2010.02370.x · Cited by 200
Manco-Johnson, M. J., Kempton, C. L., Reding, M. T., Lissitchkov, T., Goranov, S., Gercheva, L., Rusen, L., Ghinea, M., Uscatescu, V., Rescia, V., et al. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12202 · Cited by 197
Self-citationProlonged activity of factor IX as a monomeric Fc fusion protein
Peters, R. T., Low, S. C., Kamphaus, G. D., Dumont, J. A., Amari, J. V., Lu, Q., Zarbis-Papastoitsis, G., Reidy, T. J., Merricks, E. P., Nichols, T. C., et al. (2010) · Blood · doi:10.1182/blood-2009-08-239665 · Cited by 196
Treatment adherence in hemophilia
Thornburg, C., & Duncan, N. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s139851 · Cited by 195
“Patients and caregivers should also be educated that prophylaxis likely prevents microbleeds and is thus critical, even when patients are asymptomatic.(4)”
Iorio, A., Marchesini, E., Marcucci, M., Stobart, K., & Chan, A. K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003429.pub4 · Cited by 192
COLLINS, P. W., BJÖRKMAN, S., FISCHER, K., BLANCHETTE, V., OH, M., SCHROTH, P., FRITSCH, S., CASEY, K., SPOTTS, G., & EWENSTEIN, B. M. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03703.x · Cited by 185
The Vision Academy Steering Committee, Lanzetta, P., & Loewenstein, A. (2017) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3647-4 · Cited by 180
“These may be small or negligible at each event, but can accumulate and have significant long-term consequences, as demonstrated in patients with severe hemophilia A [82] and multiple sclerosis [83].”
BackgroundHaemophilia and Joint Disease: Pathophysiology, Evaluation, and Management
Knobe, K., & Berntorp, E. (2011) · Journal of Comorbidity · doi:10.15256/joc.2011.1.2 · Cited by 178
Young, G., Mahlangu, J., Kulkarni, R., Nolan, B., Liesner, R., Pasi, J., Barnes, C., Neelakantan, S., Gambino, G., Cristiano, L. M., et al. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12911 · Cited by 173
Back to the future: a recent history of haemophilia treatment
MANNUCCI, P. M. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01708.x · Cited by 175
Shapiro, A. D., Ragni, M. V., Valentino, L. A., Key, N. S., Josephson, N. C., Powell, J. S., Cheng, G., Thompson, A. R., Goyal, J., Tubridy, K. L., et al. (2012) · Blood · doi:10.1182/blood-2011-07-367003 · Cited by 173
Self-citationTiede, A., Brand, B., Fischer, R., Kavakli, K., Lentz, S. R., Matsushita, T., Rea, C., Knobe, K., & Viuff, D. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12161 · Cited by 170
Manco-Johnson, M. J., Soucie, J. M., & Gill, J. C. (2017) · Blood · doi:10.1182/blood-2016-02-683169 · Cited by 166
“This age was chosen to align as closely as possible with the Joint Outcomes Study definition, as well as with previous European definitions of primary prophylaxis.(5,13-15) c Primary prophylaxis 4 to 6 years: first documentation of routine FVIII replacement therapy at a UDC visit on or after the fourth birthday but be…”
BackgroundMethodInfluentialSelf-citationExtension of in vivo half-life of biologically active molecules by XTEN protein polymers
Podust, V. N., Balan, S., Sim, B.-C., Coyle, M. P., Ernst, U., Peters, R. T., & Schellenberger, V. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.038 · Cited by 166
“…outcomes, but have a signi fi cant treatment burden due to the short half-lives of the factors, such that hemophilia A patients on a prophylaxis regimen infuse from three times per week to every other day with FVIII, and hemophilia B patients infuse two to three times per week with FIX [88].”
KULKARNI, R., SOUCIE, J. M., LUSHER, J., PRESLEY, R., SHAPIRO, A., GILL, J., MANCO‐JOHNSON, M., KOERPER, M., MATHEW, P., ABSHIRE, T., et al. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02074.x · Cited by 168
Self-citationHow we treat a hemophilia A patient with a factor VIII inhibitor
Kempton, C. L., & White, G. C. (2009) · Blood · doi:10.1182/blood-2008-06-160432 · Cited by 163
Receptor-Mediated Endocytosis and Brain Delivery of Therapeutic Biologics
Xiao, G., & Gan, L.-S. (2013) · International Journal of Cell Biology · doi:10.1155/2013/703545 · Cited by 163
“per week to reach full prophylaxis [107].”
Joint protection in haemophilia
RODRIGUEZ‐MERCHAN, E. C., JIMENEZ‐YUSTE, V., AZNAR, J. A., HEDNER, U., KNOBE, K., LEE, C. A., LJUNG, R., QUEROL, F., SANTAGOSTINO, E., VALENTINO, L. A., et al. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02615.x · Cited by 160
Self-citationExploring the potential of genome editing CRISPR-Cas9 technology
Singh, V., Braddick, D., & Dhar, P. K. (2017) · Gene · doi:10.1016/j.gene.2016.11.008 · Cited by 160
Hemophilia A in the third millennium
Franchini, M., & Mannucci, P. M. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.06.002 · Cited by 167
“The US Joint Outcome Study (JOS), which randomized 65 boys younger than 30 months of agewith severe hemophilia A to prophylaxis or intensive on-demand therapy, established that prophylaxis initiated early in life protects from joint damage and decreases the frequency of hemarthroses and other hemorrhages [30].”
MethodCrudele, J. M., Finn, J. D., Siner, J. I., Martin, N. B., Niemeyer, G. P., Zhou, S., Mingozzi, F., Lothrop, C. D., & Arruda, V. R. (2015) · Blood · doi:10.1182/blood-2014-07-588194 · Cited by 153
Understanding haemophilic arthropathy: an exploration of current open issues
Jansen, N. W. D., Roosendaal, G., & Lafeber, F. P. J. G. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07386.x · Cited by 158
“…prospective study showed that in some cases, joint damage was seen on magnetic resonance imaging scans and radiographs, without clinical evident joint bleeds in the past, suggesting the presence of subclinical haemarthroses leading to degenerative changes in the joint (Manco-Johnson et al, 2007).”
BackgroundProlonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs
Dumont, J. A., Liu, T., Low, S. C., Zhang, X., Kamphaus, G. D., Sakorafas, P., Fraley, C., Drager, D., Reidy, T., McCue, J. T., et al. (2012) · Blood · doi:10.1182/blood-2011-08-367813 · Cited by 157
Osteoprotegerin: Multiple partners for multiple functions
Baud’huin, M., Duplomb, L., Teletchea, S., Lamoureux, F., Ruiz-Velasco, C., Maillasson, M., Redini, F., Heymann, M.-F., & Heymann, D. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.06.001 · Cited by 153
“These data are consistent with a randomized study showing that the prophylaxis with recombinant Factor VIII prevents joint damages in young haemophilic patients (Manco-Johnson et al. 2007), possibly through a decrease in osteoclastogenesis.”
ResultPathophysiology of hemophilic arthropathy and potential targets for therapy
Pulles, A. E., Mastbergen, S. C., Schutgens, R. E. G., Lafeber, F. P. J. G., & van Vulpen, L. F. D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.032 · Cited by 158
“t has been shown that joint bleeding and joint damage still occur espite adequate prophylaxis [5,9].”
BackgroundMuto, A. K. T. M., Yoshihashi, K., Takeda, M., Kitazawa, T., Soeda, T., Igawa, T., Sakamoto, Y., Haraya, K., Kawabe, Y., Shima, M., et al. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12474 · Cited by 150
Coyle, T., Reding, M. T., Lin, J., Michaels, L. A., Shah, A., & Powell, J. S. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12506 · Cited by 145
Musculoskeletal Complications of Hemophilia
Rodriguez-Merchan, E. C. (2009) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1007/s11420-009-9140-9 · Cited by 144
Ohmori, T., Nagao, Y., Mizukami, H., Sakata, A., Muramatsu, S., Ozawa, K., Tominaga, S., Hanazono, Y., Nishimura, S., Nureki, O., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04625-5 · Cited by 149
Négrier, C., Seuser, A., Forsyth, A. L., Lobet, S., Llinás, A., Rosas, M., & Heijnen, L. (2013) · Haemophilia · doi:10.1111/hae.12118 · Cited by 146
Blanchette, V. S., Shapiro, A. D., Liesner, R. J., NAVARRO, F. H., Warrier, I. A., Schroth, P., Spotts, G. E., & Ewenstein, B. M. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03032.x · Cited by 141
Self-citationNathwani, A. C. (2019) · Hematology · doi:10.1182/hematology.2019000007 · Cited by 140
“If started in early childhood, arthropathy can be largely prevented by regular prophylaxis.(3) When continued throughout life, prophylaxis leads to near normalization of life expectancy.”
BackgroundCollins, P. W., Faradji, A., Morfini, M., Enriquez, M. M., & Schwartz, L. A. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03650.x · Cited by 140
Lundin, B., Manco-Johnson, M. L., Ignas, D. M., Moineddin, R., Blanchette, V. S., Dunn, A. L., Gibikote, S., Keshava, S. N., Ljung, R. C. R., Manco‐Johnson, M. J., et al. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02883.x · Cited by 145
Self-citationShima, M., Hanabusa, H., Taki, M., Matsushita, T., Sato, T., Fukutake, K., Kasai, R., Yoneyama, K., Yoshida, H., & Nogami, K. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017006684 · Cited by 133
Richards, M., Williams, M., Chalmers, E. A., Liesner, R. J., Collins, P. W., Vidler, V., & Hanley, J. P. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08139.x · Cited by 132
VERITAS‐Pro: a new measure of adherence to prophylactic regimens in haemophilia
Duncan, N., Kronenberger, W. G., Roberson, C., & Shapiro, A. D. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02129.x · Cited by 132
Self-citationWarren, B. B., Thornhill, D., Stein, J. M., Fadell, M., Ingram, J. D., Funk, S. M., Norton, K. L., Lane, H. D., Bennett, C. M., Dunn, A. L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001311 · Cited by 131
“*Data from Manco-Johnson et al.(4) †For JOS, relative risk of MRI OC damage at age 6 years (episodic/prophylaxis) was 6.”
BackgroundMethodInfluentialSelf-citationAdeno-Associated Virus Gene Therapy for Hemophilia
Samelson‐Jones, B. J., & George, L. A. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-033013 · Cited by 150
Mancuso, M. E., Mahlangu, J. N., & Pipe, S. W. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32722-7 · Cited by 139
Optimal management of hemophilic arthropathy and hematomas
Lobet, S., Hermans, C. R. J. R., & Lambert, C. (2014) · Journal of Blood Medicine · doi:10.2147/jbm.s50644 · Cited by 128
“This potentially causal relationship is still subject to frequent debate, as some patients with significant joint damage experience few episodes of clinically diagnosed hemarthrosis, despite having developed first arthropathy signs revealed by magnetic resonance imaging (MRI).(13) It is likely that hemophilia is assoc…”
Ultrasound detects joint damage and bleeding in haemophilic arthropathy: a proposal of a score
Melchiorre, D., Linari, S., Innocenti, M., Biscoglio, I., TOIGO, M., Matucci‐Cerinic, M., & Morfini, M. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02380.x · Cited by 127
Current clinical applications of AAV-mediated gene therapy
Byrne, B. J., Flanigan, K. M., Matesanz, S. E., Finkel, R. S., Waldrop, M. A., D'Ambrosio, E. S., Johnson, N. E., Smith, B. K., Bönnemann, C. G., Carrig, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.045 · Cited by 159
“171,194,195 Although a defined threshold of therapeutic FVIII activity is not established, epidemiologic studies demonstrate that FVIII activity of >12%–20% protects against spontaneous joint bleeds.”
Rapid musculoskeletal ultrasound for painful episodes in adult haemophilia patients
Čeponis, A., Wong-Sefidan, I., Glass, C. S., & von Drygalski, A. (2013) · Haemophilia · doi:10.1111/hae.12175 · Cited by 125
Burden of illness: direct and indirect costs among persons with hemophilia A in the United States
Zhou, Z., Koerper, M. A., Johnson, K. A., Riske, B., Baker, J., Ullman, M. M., Curtis, R., Poon, J. L., Lou, M., & Nichol, M. B. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1016228 · Cited by 125
“Persons with hemophilia A were eligible for this study if they met these inclusion criteria: (1) aged 2–64 years as of the date of initial interview; (2) factor VIII level 30%, with or without a history of inhibitor; (3) received at least 90% of their hemophilia care at an HTC; (4) obtained HTC care within 2 years pri…”
MethodSelf-citationEffects of secondary prophylaxis started in adolescent and adult haemophiliacs
Tagliaferri, A., Franchini, M., Coppola, A., Rivolta, G. F., Santoro, C., ROSSETTI, G., FEOLA, G., Zanon, E., Dragani, A., Iannaccaro, P., et al. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01791.x · Cited by 124
Effect of late prophylaxis in hemophilia on joint status: a randomized trial
Manco‐Johnson, M. J., Lundin, B., Funk, S. M., PETERFY, C. G., Raunig, D. L., Werk, M., Kempton, C. L., Reding, M. T., Goranova-Marinova, V. S., Gercheva, L., et al. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13811 · Cited by 124
Self-citationAssociation Between Physical Activity and Risk of Bleeding in Children With Hemophilia
Broderick, C. R., Herbert, R., Latimer, J., Barnes, C. D., Curtin, J. A., Mathieu, E., Monagle, P., & Brown, S. A. (2012) · JAMA · doi:10.1001/jama.2012.12727 · Cited by 123
Diagnostic Accuracy of Ultrasound for Assessment of Hemophilic Arthropathy: MRI Correlation
Doria, A. S., Keshava, S. N., Mohanta, A., Jarrin, J. R., Blanchette, V. S., Srivastava, A., Moineddin, R., KAVITHA, M. L., Hilliard, P., Poonnoose, P. M., et al. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.14.12501 · Cited by 123
“Prior clinical trials on children with hemophilia [9, 10] have used MRI-detected structural joint damage, defined as the presence of a subchondral cyst, surface erosion, or cartilage loss representing osteochondral change, to indicate treatment failure (outcome measure).”
BackgroundSafety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII
Reding, M. T., Ng, H. J. H., Poulsen, L. H., Eyster, M. E., Pabinger, I., Shin, H., Walsch, R., Lederman, M. M., Wang, M., Hardtke, M., et al. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13597 · Cited by 124
Practical aspects of extended half-life products for the treatment of haemophilia
Lambert, T., Benson, G. M., Dolan, G., Hermans, C. R. J. R., Jiménez‐Yuste, V., Ljung, R. C. R., Morfini, M., Zupančić‐Šalek, S., & Santagostino, E. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718796429 · Cited by 122
Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A
Giangrande, P. L. F., Andreeva, T. A., Chowdary, P., Ehrenforth, S., Hanabusa, H., Leebeek, F. W. G., Lentz, S. R., Nemes, L., Poulsen, L. H., Santagostino, E., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-06-0444 · Cited by 122
“In children and many adults with severe haemophilia A, prophylactic FVIII replacement is preferred to on-demand therapy because it reduces the frequency of bleeds and prevents the development of chronic arthropathy (1).”
BackgroundWitmer, C. M., Presley, R. J., Kulkarni, R., Soucie, J. M., Manno, C. S., & Raffini, L. J. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08469.x · Cited by 120
Self-citationSabatino, D. E., Lange, A. M., Altynova, E. S., Sarkar, R., Zhou, S., Merricks, E. P., Franck, H. W. G., Nichols, T. C., Arruda, V. R., & Kazazian, H. H. (2010) · Molecular Therapy · doi:10.1038/mt.2010.240 · Cited by 124
Zimmerman, B., & Valentino, L. A. (2013) · Pediatrics in Review · doi:10.1542/pir.34-7-289 · Cited by 120
Self-citationTreatment of hemophilia: a review of current advances and ongoing issues
Coppola, A. (2010) · Journal of Blood Medicine · doi:10.2147/jbm.s6885 · Cited by 119
“Interestingly, only the MRI assessment showed a significant difference in joint outcome, with more than half the joint abnormalities being not detectable by conventional radiologic evaluation.(28) The JOS study confirmed that MRI is the preferable imaging technique in hemophilic children, also being able to reveal sig…”
InfluentialAchieving the unimaginable: Health equity in haemophilia
Skinner, M. W., Nugent, D. J., Wilton, P., O’Mahony, B., Dolan, G., O’Hara, J., & Berntorp, E. E. (2019) · Haemophilia · doi:10.1111/hae.13862 · Cited by 124
Self-citationCoppola, A., Franchini, M., Makris, M., Santagostino, E., Minno, G. D., & Mannucci, P. M. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02758.x · Cited by 121
Nathwani, A. C. (2022) · Hematology · doi:10.1182/hematology.2022000388 · Cited by 135
Neoangiogenesis contributes to the development of hemophilic synovitis
Acharya, S. S., Kaplan, R. N., MacDonald, D. D., Fabiyi, O. T., DiMichele, D., & Lyden, D. C. (2010) · Blood · doi:10.1182/blood-2010-05-284653 · Cited by 125
Self-citationAbshire, T. C., Federici, A. B., Alvárez, M. T., Bowen, J. M., Carcao, M. D., Gill, J. C., Key, N. S., Kouides, P. A., Kurnik, K., Lail, A. E., et al. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02916.x · Cited by 118
“Prophylaxis can be implemented early in life in a home setting, and prevention of bleeding and its consequences is possible [10,11].”
Self-citationStennicke, H. R., Kjalke, M., Karpf, D. M., Balling, K. W., Johansen, P. B., Elm, T., Øvlisen, K., Møller, F., Holmberg, H. L., Gudme, C. N., et al. (2013) · Blood · doi:10.1182/blood-2012-01-407494 · Cited by 119
Metadata
- Authors
- Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., Valentino, L. A., Hoots, W. K., Buchanan, G. R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G. A., Thompson, A. A., McRedmond, K., Soucie, J. M., Austin, H., & Evatt, B. L.
- Affiliations
- University of Colorado Denver (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-08-09
- Volume
- 357
- Issue
- 6
- Pages
- 535-544
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2167801052
- Cited by
- 1,950
- References
- 27
- Citations by year
- 2026: 57 · 2025: 70 · 2024: 98 · 2023: 115 · 2022: 106 · 2021: 123 · 2020: 127 · 2019: 110 · 2018: 114 · 2017: 107 · 2016: 123 · 2015: 116 · 2014: 131 · 2013: 116 · 2012: 112
- FWCI
- 45.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (U27/CCU812106, R00069)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hemophilia A, severe hemophilia, prophylaxis, episodic treatment, recombinant factor VIII, joint destruction, factor VIII inhibitors, joint hemorrhage, children, central venous catheter complications
- MeSH terms
- Child, Child, Preschool, Drug Administration Schedule, Factor VIII, Follow-Up Studies, Hemarthrosis, Hemophilia A, Hemorrhage, Humans, Infant, Infusions, Intravenous, Joint Diseases, Male, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.